Ratings by BTIG (Kaveri Pohlman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/31/2024 | MacroGenics | MGNX | Downgrade | Neutral (Buy) |
5.25 (4.38) |
-16.57% | Details | |
| 7/18/2024 | Nuvation Bio Inc | NUVB | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2024 | Shattuck Labs | STTK | Maintain | Neutral (N/A) |
|
Details | ||
| 6/27/2024 | Genmab A/S | GMAB | Maintain | Buy (N/A) |
|
Details | ||
| 4/17/2024 | Cullinan Oncology Inc. | CGEM | Maintain | Buy (N/A) |
|
Details | ||
| 4/16/2024 | Xencor, Inc. | XNCR | Maintain | Buy (N/A) |
|
Details | ||
| 4/2/2024 | Gritstone bio | GRTS | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2024 | Nuvation Bio Inc | NUVB | Upgrade | Buy (Neutral) |
2.25 (5.83) |
159.11% | Details | |
| 3/21/2024 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
38.63 (14.22) |
-63.19% | Details | |
| 3/4/2024 | MacroGenics | MGNX | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2024 | Mersana | MRSN | Upgrade | Buy (Neutral) |
4.27 (29.08) |
581.03% | Details | |
| 2/9/2024 | Pyxis Oncology Inc. | PYXS | New Coverage | Buy (N/A) |
3.71 (2.13) |
-42.59% | Details | |
| 1/8/2024 | Ambrx Biopharma | AMAM | Downgrade | Neutral (Buy) |
13.63 (28.00) |
105.43% | Details | |
| 12/19/2023 | Exelixis | EXEL | New Coverage | Buy (N/A) |
23.34 (51.27) |
119.67% | Details | |
| 12/6/2023 | Replimune Group | REPL | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2023 | Arcus Biosciences | RCUS | Maintain | Buy (N/A) |
|
Details | ||
| 10/13/2023 | Genmab A/S | GMAB | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2023 | Ambrx Biopharma | AMAM | New Coverage | Buy (N/A) |
11.64 (28.00) |
140.55% | Details | |
| 8/24/2023 | Genmab A/S | GMAB | New Coverage | Buy (N/A) |
37.35 (25.54) |
-31.62% | Details | |
| 7/27/2023 | Mersana | MRSN | Downgrade | Neutral (Buy) |
3.91 (4.27) |
9.21% | Details | |
| 6/15/2023 | Mersana | MRSN | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2023 | BioAtla Inc. | BCAB | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2023 | MacroGenics | MGNX | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2023 | Mersana | MRSN | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2023 | G1 Therapeutics | GTHX | Maintain | Buy (N/A) |
|
Details | ||
| 11/21/2022 | Cullinan Oncology Inc. | CGEM | New Coverage | Buy (N/A) |
12.41 (17.03) |
37.23% | Details | |
| 11/14/2022 | OncoSec Medical | ONCS | Downgrade | Neutral (Buy) |
4.14 (0.28) |
-93.24% | Details | |
| 8/31/2022 | Shattuck Labs | STTK | New Coverage | Buy (N/A) |
3.03 (5.23) |
72.61% | Details | |
| 8/2/2022 | Nuvation Bio Inc | NUVB | Downgrade | Neutral (Buy) |
2.76 (5.83) |
111.23% | Details | |
| 7/7/2022 | CytomX Therapeutics | CTMX | Maintain | Buy (N/A) |
|
Details | ||
| 4/20/2022 | Checkmate Pharmaceuticals | CMPI | Downgrade | Neutral (Buy) |
10.35 (10.50) |
1.45% | Details | |
| 3/30/2022 | Checkmate Pharmaceuticals | CMPI | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2022 | OncoSec Medical | ONCS | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2022 | Oncternal Therapeutics | ONCT | New Coverage | Buy (N/A) |
1.73 (0.53) |
-69.36% | Details | |
| 2/9/2022 | Sonnet BioTherapeutics | SONN | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2021 | Arcus Biosciences | RCUS | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2021 | CytomX Therapeutics | CTMX | New Coverage | Buy (N/A) |
7.02 (3.07) |
-56.27% | Details | |
| 11/10/2021 | Mersana | MRSN | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2021 | Mersana | MRSN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/15/2021 | G1 Therapeutics, Inc. | GTHX | New Coverage | Buy (N/A) |
5.98 (7.15) |
19.57% | Details | |
| 10/14/2021 | BioAtla Inc. | BCAB | New Coverage | Buy (N/A) |
27.46 (3.88) |
-85.87% | Details | |
| 10/14/2021 | Checkmate Pharmaceuticals | CMPI | New Coverage | Buy (N/A) |
4.03 (10.35) |
156.82% | Details | |
| 10/14/2021 | Gritstone Oncology | GRTS | New Coverage | Buy (N/A) |
9.20 (0.03) |
-99.67% | Details | |
| 10/14/2021 | MacroGenics | MGNX | New Coverage | Buy (N/A) |
20.94 (5.25) |
-74.93% | Details | |
| 10/14/2021 | Mersana | MRSN | New Coverage | Buy (N/A) |
8.66 (29.08) |
235.8% | Details | |
| 10/14/2021 | Nuvation Bio Inc | NUVB | New Coverage | Buy (N/A) |
9.50 (5.83) |
-38.63% | Details | |
| 10/14/2021 | OncoSec Medical | ONCS | New Coverage | Buy (N/A) |
1.90 (0.28) |
-85.26% | Details | |
| 10/14/2021 | Replimune Group | REPL | New Coverage | Buy (N/A) |
31.16 (11.11) |
-64.35% | Details | |
| 10/14/2021 | Seagen | SGEN | New Coverage | Neutral (N/A) |
167.86 (228.74) |
36.27% | Details | |
| 10/14/2021 | Xencor, Inc. | XNCR | New Coverage | Buy (N/A) |
38.69 (13.98) |
-63.87% | Details | |
| 10/14/2021 | Arcus Biosciences | RCUS | New Coverage | Buy (N/A) |
31.38 (26.96) |
-14.09% | Details | |
| 9/15/2021 | Sonnet BioTherapeutics | SONN | New Coverage | Buy (N/A) |
0.56 (1.26) |
125% | Details |
